Published in AIDS Weekly, May 17th, 1999
Leukine, which stimulates the immune system, kept the virus suppressed and extended the use of antiretroviral drug cocktails in AIDS patients with low levels of the virus in their bodies, the biotechnology company said in a statement.
The Phase III study showed that Leukine also reduced the incidence of all infections and death, Immunex said.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.